A clinically differentiated urology robotics disruptor re-rating from “hypergrowth” to “disciplined scale,” with HYDROS + Category I reimbursement setting up a utilization-and-margin driven path to profitability—if execution holds.
Overview
PROCEPT BioRobotics is a commercial-stage surgical robotics company focused on BPH, leveraging Aquablation therapy delivered via AQUABEAM and the next-generation, AI-powered HYDROS robotic system. The company’s thesis is that a standardized, image-guided, heat-free robotic approach can outperform traditional manual/heat-based interventions by delivering durable outcomes less dependent on surgeon skill and prostate anatomy. The model combines capital system placements with recurring single-use handpieces (razor/razorblade), creating a long revenue tail once installed. FY2025 revenue reached ~$308.1M (+37% YoY) with a U.S.-led installed base of 718 systems and estimated ~10–25% penetration of the surgical BPH market within an addressable opportunity described as ~$30B. A strategic shift is underway under new leadership to improve revenue quality: eliminating bulk discounting, aligning consumable shipments to real procedures, and pushing ASPs higher. With Category I reimbursement starting in 2026 and a potential second indication (localized prostate cancer) via the WATER IV trial, the company is positioned for strong growth, but must execute through near-term volatility and reach an EBITDA inflection to avoid dilution.